SHP-1 is a target of regorafenib in colorectal cancer

Oncotarget

Volumn 5, Issue 15, 2014, Pages 6243-6251

  Fan, Li Ching ^a   Teng, Hao Wei ^b,c   Shiau, Chung Wai ^c   Lin, Hang ^a   Hung, Man Hsin ^b,c   Chen, Yen Lin ^d   Huang, Jui Wen ^e   Tai, Wei Tien ^a   Yu, Hui Chuan ^a   Chen, Kuen Feng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

Author keywords

Apoptosis; Colorectal cancer; Regorafenib; SHP 1; STAT3

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE SHP 1; REGORAFENIB; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PTPN6 PROTEIN, HUMAN; PYRIDINE DERIVATIVE; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER TISSUE; CELL PROLIFERATION; COLORECTAL CANCER; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMID; POINT MUTATION; PROTEIN DOMAIN; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL GROWTH; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; HCT116 CELL LINE; HT 29 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL GROWTH PROCESSES; COLORECTAL NEOPLASMS; DOWN-REGULATION; HCT116 CELLS; HT29 CELLS; HUMANS; MICE; MICE, NUDE; PHENYLUREA COMPOUNDS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PYRIDINES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906268735     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2191     Document Type: Article

References (25)

1. Center MM, Jemal A, Smith RA and Ward E. Worldwide variations in colorectal cancer. CA: a cancer journal for clinicians. 2009; 59(6):366-378.
2. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, Thierauch KH and Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International journal of cancer Journal international du cancer. 2011; 129(1):245-255.
3. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863):303-312.
4. Schmieder R, Hoffmann J, Becker M, Bhargava A, Muller T, Kahmann N, Ellinghaus P, Adams R, Rosenthal A, Thierauch KH, Scholz A, Wilhelm SM and Zopf D. Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer. International journal of cancer Journal international du cancer. 2013.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, et al. Sorafenib in advanced hepatocellular carcinoma. The New England journal of medicine. 2008; 359(4):378-390.
6. Chen KF, Tai WT, Hsu CY, Huang JW, Liu CY, Chen PJ, Kim I and Shiau CW. Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. European journal of medicinal chemistry. 2012; 55:220-227.
7. Tai WT, Shiau CW, Chen PJ, Chu PY, Huang HP, Liu CY, Huang JW and Chen KF. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Hepatology. 2014; 59(1):190-201.
8. Banville D, Stocco R and Shen SH. Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts. Genomics. 1995; 27(1):165-173.
9. Mok SC, Kwok TT, Berkowitz RS, Barrett AJ and Tsui FW. Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer. Gynecologic oncology. 1995; 57(3):299-303.
10. Tsui HW, Hasselblatt K, Martin A, Mok SC and Tsui FW. Molecular mechanisms underlying SHP-1 gene expression. European journal of biochemistry / FEBS. 2002; 269(12):3057-3064.
11. Wu C, Sun M, Liu L and Zhou GW. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene. 2003; 306:1-12.
12. Witkiewicz A, Raghunath P, Wasik A, Junkins-Hopkins JM, Jones D, Zhang Q, Odum N and Wasik MA. Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma. Human pathology. 2007; 38(3):462-467.
13. Lopez-Ruiz P, Rodriguez-Ubreva J, Cariaga AE, Cortes MA and Colas B. SHP-1 in cell-cycle regulation. Anti cancer agents in medicinal chemistry. 2011; 11(1):89-98.
14. Wu C, Guan Q, Wang Y, Zhao ZJ and Zhou GW. SHP- 1 suppresses cancer cell growth by promoting degradation of JAK kinases. Journal of cellular biochemistry. 2003; 90(5):1026-1037.
15. Yang J, Liang X, Niu T, Meng W, Zhao Z and Zhou GW. Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1. The Journal of biological chemistry. 1998; 273(43):28199-28207.
16. Yang J, Liu L, He D, Song X, Liang X, Zhao ZJ and Zhou GW. Crystal structure of human protein-tyrosine phosphatase SHP-1. The Journal of biological chemistry. 2003; 278(8):6516-6520.
17. Qin C, Wavreille AS and Pei D. Alternative mode of binding to phosphotyrosyl peptides by Src homology-2 domains. Biochemistry. 2005; 44(36):12196-12202.
18. Sweeney MC, Wavreille AS, Park J, Butchar JP, Tridandapani S and Pei D. Decoding protein-protein interactions through combinatorial chemistry: sequence specificity of SHP-1, SHP-2, and SHIP SH2 domains. Biochemistry. 2005; 44(45):14932-14947.
19. Wang W, Liu L, Song X, Mo Y, Komma C, Bellamy HD, Zhao ZJ and Zhou GW. Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation. Journal of cellular biochemistry. 2011; 112(8):2062-2071.
20. Barr AJ, Ugochukwu E, Lee WH, King ON, Filippakopoulos P, Alfano I, Savitsky P, Burgess-Brown NA, Muller S and Knapp S. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell. 2009; 136(2):352-363.
21. Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ and Cheng AL. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti- DR5 antibody, through SHP-1-dependent inhibition of STAT3. Biochemical pharmacology. 2012; 83(6):769-777.
22. Chen KF, Su JC, Liu CY, Huang JW, Chen KC, Chen WL, Tai WT and Shiau CW. A novel obatoclax derivative, SC- 2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation. Cancer letters. 2012; 321(1):27-35.
23. Li R, Hu Z, Sun SY, Chen ZG, Owonikoko TK, Sica GL, Ramalingam SS, Curran WJ, Khuri FR and Deng X. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Molecular cancer therapeutics. 2013; 12(10):2200- 2212. 24. Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, Shiau CW and Chen KF. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast cancer research: BCR. 2013; 15(4):R63. 25. Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX and Fang JY. Inhibition of JAK1, 2/ STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia. 2008; 10(3):287-297.
24. Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, Shiau CW and Chen KF. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast cancer research: BCR. 2013; 15(4):R63.
25. Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX and Fang JY. Inhibition of JAK1, 2/ STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia. 2008; 10(3):287-297